Etcamah (camizestrant)
AstraZeneca (AZN)
ApprovedSep 4, 2026
Marketer take
Labeled for switching when an ESR1 mutation is detected during aromatase inhibitor plus CDK4/6 therapy, which makes mutation testing during first-line treatment the core message, and it competes with Orserdu and Veppanu in ESR1-mutated disease.
- Sponsor company
- AstraZeneca (AZN)
- Indication
- To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy
- Therapeutic area
- Oncology
- Event
- FDA approval
- Date
- Sep 4, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?